Miglustat treatment may reduce cerebrospinal fluid levels of the axonal degeneration marker Tau in Niemann–Pick type C

JIMD Reports

Volumn 3, Issue , 2012, Pages 45-52

  Mattsson, Niklas ^a   Zetterberg, Henrik ^a   Bianconi, Simona ^b   Yanjanin, Nicole M ^b   Fu, Rao ^b   Månsson, Jan Eric ^a   Porter, Forbes D ^b   Blennow, Kaj ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

Author keywords

Amyloid metabolism; Autosomal recessive lysosomal storage disorder; Axonal degeneration; Miglustat therapy; Miglustat treatment

Indexed keywords

EID: 84871452700     PISSN: 21928304     EISSN: 21928312     Source Type: Book Series    
DOI: 10.1007/8904_2011_47     Document Type: Chapter

References (41)

1. Andreasson U, Portelius E, Andersson ME, Blennow K, Zetterberg H (2007) Aspects of beta-amyloid as a biomarker for Alzheimer’s disease. Biomarkers Med 1:59–78
2. Blennow K, Zetterberg H, Minthon L et al (2007) Longitudinal stability of CSF biomarkers in Alzheimer’s disease. Neurosci Lett 419:18–22
3. Galanaud D, Tourbah A, Lehericy S et al (2009) 24 month-treatment with miglustat of three patients with Niemann-Pick disease type C: follow up using brain spectroscopy. Mol Genet Metab 96:55–8
4. Gilman S, Koller M, Black RS et al (2005) Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology 64:1553–62
5. Grimm MO, Grimm HS, Hartmann T (2007) Amyloid beta as a regulator of lipid homeostasis. Trends Mol Med 13:337–44
6. Hampel H, Blennow K, Shaw LM, Hoessler YC, Zetterberg H, Trojanowski JQ (2009) Total and phosphorylated tau protein as biological markers of Alzheimer’s disease. Exp Gerontol 45:30–40
7. Hesse C, Rosengren L, Andreasen N et al (2001) Transient increase in total tau but not phospho-tau in human cerebrospinal fluid after acute stroke. Neurosci Lett 297:187–90
8. Hirsch-Reinshagen V, Burgess BL, Wellington CL (2009) Why lipids are important for Alzheimer disease? Mol Cell Biochem 326:121–9
9. Imrie J, Dasgupta S, Besley GT et al (2007) The natural history of Niemann-Pick disease type C in the UK. J Inherit Metab Dis 30:51–9
10. Jin LW, Shie FS, Maezawa I, Vincent I, Bird T (2004) Intracellular accumulation of amyloidogenic fragments of amyloid-beta precursor protein in neurons with Niemann-Pick type C defects is associated with endosomal abnormalities. Am J Pathol 164:975–85
11. Kagedal K, Kim WS, Appelqvist H et al (2010) Increased expression of the lysosomal cholesterol transporter NPC1 in Alzheimer’s disease. Biochim Biophys Acta 1801:831–8
12. Kodam A, Maulik M, Peake K et al (2010) Altered levels and distribution of amyloid precursor protein and its processing enzymes in Niemann-Pick type C1-deficient mouse brains. Glia 58:1267–81
13. Kosicek M, Malnar M, Goate A, Hecimovic S (2010) Cholesterol accumulation in Niemann Pick type C (NPC) model cells causes a shift in APP localization to lipid rafts. Biochem Biophys Res Commun 393:404–9
14. Lee JH, Yu WH, Kumar A et al (2010) Lysosomal proteolysis and autophagy require presenilin 1 and are disrupted by Alzheimer-related PS1 mutations. Cell 141:1146–58
15. Liu RQ, Zhou QH, Ji SR et al (2010) Membrane localization of beta-amyloid 1–42 in lysosomes: a possible mechanism for lysosome labilization. J Biol Chem 285:19986–96
16. Lloyd-Evans E, Platt FM (2010) Lipids on trial: the search for the offending metabolite in Niemann-Pick type C disease. Traffic 11:419–28
17. Lorenzen A, Samosh J, Vandewark K et al (2010) Rapid and direct transport of cell surface APP to the lysosome defines a novel selective pathway. Mol Brain 3:11
18. Malnar M, Kosicek M, Mitterreiter S et al (2010) Niemann-Pick type C cells show cholesterol dependent decrease of APP expression at the cell surface and its increased processing through the beta-secretase pathway. Biochim Biophys Acta 1802:682–91
19. Mattsson N, Savman K, Osterlundh G, Blennow K, Zetterberg H (2010) Converging molecular pathways in human neural development and degeneration. Neurosci Res 66:330–2
20. Mattsson N, Zetterberg H, Bianconi S et al (2011) Gamma-secretase-dependent amyloid-beta is increased in Niemann-Pick type C: a cross-sectional study. Neurology 76:366–72
21. Naureckiene S, Sleat DE, Lackland H et al (2000) Identification of HE1 as the second gene of Niemann-Pick C disease. Science 290:2298–301
22. Olsson A, Vanderstichele H, Andreasen N et al (2005) Simultaneous measurement of beta-amyloid(1–42), total tau, and phosphory-phosphory-lated tau (Thr181) in cerebrospinal fluid by the xMAP technology. Clin Chem 51:336–45 lated
23. Ory DS (2004) The niemann-pick disease genes; regulators of cellular cholesterol homeostasis. Trends Cardiovasc Med 14:66–72
24. Patterson MC, Vecchio D, Prady H, Abel L, Wraith JE (2007) Miglustat for treatment of Niemann-Pick C disease: a randomised controlled study. Lancet Neurol 6:765–72
25. Patterson MC, Vecchio D, Jacklin E et al (2010) Long-term miglustat therapy in children with Niemann-Pick disease type C. J Child Neurol 25:300–5
26. Pentchev PG, Comly ME, Kruth HS et al (1987) Group C Niemann-Pick disease: faulty regulation of low-density lipoprotein uptake and cholesterol storage in cultured fibroblasts. FASEB J 1:40–5
27. Pineda M, Wraith JE, Mengel E et al (2009) Miglustat in patients with Niemann-Pick disease Type C (NP-C): a multicenter observational retrospective cohort study. Mol Genet Metab 98:243–9
28. Platt FM, Lachmann RH (2009) A new surrogate marker for CNS pathology in Niemann-Pick disease type C? Mol Genet Metab 96:53–4
29. Querfurth HW, LaFerla FM (2010) Alzheimer’s disease. N Engl J Med 362:329–44
30. Sevin M, Lesca G, Baumann N et al (2007) The adult form of Niemann-Pick disease type C. Brain 130:120–33
31. Vanier MT, Millat G (2003) Niemann-Pick disease type C. Clin Genet 64:269–81
32. Wraith JE, Baumgartner MR, Bembi B et al (2009) Recommendations on the diagnosis and management of Niemann-Pick disease type C. Mol Genet Metab 98:152–65
33. Wraith JE, Vecchio D, Jacklin E et al (2010) Miglustat in adult and juvenile patients with Niemann-Pick disease type C: long-term data from a clinical trial. Mol Genet Metab 99:351–7
34. Yanjanin NM, Velez JI, Gropman A et al (2010) Linear clinical progression, independent of age of onset, in Niemann-Pick disease, type C. Am J Med Genet B Neuropsychiatr Genet 153B:132–40
35. Yerushalmi B, Sokol RJ, Narkewicz MR, Smith D, Ashmead JW, Wenger DA (2002) Niemann-pick disease type C in neonatal cholestasis at a North American Center. J Pediatr Gastroenterol Nutr 35:44–50
36. Zachrisson OC, Balldin J, Ekman R et al (2000) No evident neuronal damage after electroconvulsive therapy. Psychiatry Res 96:157–65
37. Zervas M, Dobrenis K, Walkley SU (2001a) Neurons in Niemann-Pick disease type C accumulate gangliosides as well as unesterified cholesterol and undergo dendritic and axonal alterations. J Neuropathol Exp Neurol 60:49–64
38. Zervas M, Somers KL, Thrall MA, Walkley SU (2001b) Critical role for glycosphingolipids in Niemann-Pick disease type C. Curr Biol 11:1283–7
39. Zetterberg H, Hietala MA, Jonsson M et al (2006) Neurochemical aftermath of amateur boxing. Arch Neurol 63:1277–80
40. Zetterberg H, Pedersen M, Lind K et al (2007) Intra-individual stability of CSF biomarkers for Alzheimer’s disease over two years. J Alzheimers Dis 12:255–60
41. Zetterberg H, Blennow K, Hanse E (2010) Amyloid beta and APP as biomarkers for Alzheimer’s disease. Exp Gerontol 45:23–9